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Background: Hyperkalemia is an infrequent but potentially serious complication of low molecular weight heparin
(LMWH) use. While there are a number of trials comparing LMWH to unfractionated heparin (UFH) there is no
comparison of the risk with LMWH versus placebo. Aim of the present post-hoc analysis of the PARAT trial was the
description of serum potassium levels with certoparin compared to placebo.
Results: PARAT was a double-blind, placebo-controlled, randomized trial in patients with coronary artery disease
receiving either 8,000 I.U. aXa per day or placebo. Serum potassium was monitored at baseline and at scheduled
follow-up visits at 2 and 4–6 weeks and 3 and 4–6 months. Statistical evaluation included paired, two sided t-test
for each of the treatment groups to compare baseline and follow-up values. A total of 117 patients (59 certoparin,
58 placebo) were included with a mean age of 59 years and 84.6% male gender. There was a statistically significant
increase in serum potassium at two weeks after discharge compared to baseline (p < 0.001) in either group which
remained elevated throughout the three months treatment phase. Differences between treatment groups were not
statistically significant. After treatment discontinuation at the three months’ visit serum potassium returned to
normal values (p = n.s. vs. baseline) in both groups. Overall 12 out of 59 patients receiving certoparin (20.3%) and 11
out of 58 patients receiving placebo (19.0%) experienced hyperkalemia based on threshold of >5.0 mmol/l at any
time during the observation.
Conclusions: We conclude that there is no incremental risk of hyperkalemia with certoparin up to 8,000 I.U. aXa
per day versus placebo in patients with coronary artery disease. The increase in serum potassium values in either
group calls for clinical surveillance and the consideration of further risk factors predisposing to hyperkalemia.
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unless otherwise stated.Hyperkalemia has been reported to be a rare adverse
event of heparin treatment, an increase of serum potas-
sium > 5 mmol/l having been observed in 7% of patients
receiving UFH and 15% among those receiving LMWH
[1]. It has been described to be a consequence of (revers-
ible) aldosterone suppression, which occurs within a few
days after treatment initiation [2-4]. This side effect is
more common in the elderly, in patients with renal
insufficiency and in those with diabetes mellitus [5].
More recent data report an increase of serum potas-
sium with either heparin type (LMWH or UFH) with
no statistically significant differences between groupsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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during follow-up were potassium levels at baseline,
serum creatinine, and creatinine clearance [6].
While there are data on bemiparin [7], nadroparin [2]
and enoxaparin [2,6,8] insufficient data are available for
long-term use and in patients with coronary artery dis-
ease. Furthermore there is no placebo controlled trial
and hyperkalemia has up to date not been described for
certoparin use from clinical trials. Therefore we did a
post-hoc analysis of a randomized trial on the use of the
low molecular weight heparin versus placebo in patients
undergoing coronary angioplasty [9] aiming to describe
serum potassium levels with certoparin use and to com-
pare these to placebo.
Methods
This was a post-hoc analysis of the Prophylaxis Against
Restenosis Angioplasty Trial (PARAT) which was a
double-blind, placebo-controlled, randomized trial with
two study groups conducted at four medical centres, the
results of which having been previously reported [9].
The protocol was approved by the institutional review
boards of each institution. Patients referred for elective
balloon angioplasty were asked to participate and to pro-
vide written informed consent. Only balloon angioplasty
was specified in order to avoid confounding treatment
methods. Angiography was repeated at the end of a
6-months observation period.
Inclusion and exclusion criteria
Patients were required to be at an age between 21 and
80 years, have significant coronary artery disease (CAD,
defined as stenosis > 50%), and be able to give informed
consent. Excluding conditions were congestive heart fail-
ure, other major illnesses (i.e., cancer, liver disease, renal
failure, etc.), severe hypertension, child bearing potential,
coronary artery bypass surgery (CABG) within 6 weeks,
oral anticoagulation therapy, active ulcer or gastrointes-
tinal bleeding, thrombocytopenia, coagulopathy, severe
osteoporosis, any cerebral vascular accident (CVA) or
transient ischemic attack (TIA), severe diabetic retinopathy,
hypersensitivity to heparin or LMWH, or participation in a
clinical drug trial within the last 4 weeks.
Randomization and drug treatment
After coronary angioplasty, patients were monitored at
the coronary care unit for 12–36 hours. UFH infusion
was initiated at 1,000 I.U. per hour and continued for an
additional 12–24 hours to maintain the activated parital
thromboplastin time (aPTT) between 60–80 seconds or
an activated clotting time (ACT) of 250–300 seconds.
Then, patients were randomly assigned to treatment with
subcutaneous injections of LMWH (certoparin 8,000 I.U.
antiXa) or placebo for 3 months. Thirty minutes afterterminating UFH, the first dose of study medication was
applied by the study nurse coordinator subcutaneously
between 6 and 10 am on the first day after percutaneous
coronary intervention (PTCA) who then supervised the
self-administered injections until the patient was dis-
charged. Thereafter, over a period of three months, pa-
tients had to self administer a subcutaneous injection of
certoparin 8000 I.U. aXa or placebo equivalent every
morning between 8 and 10 am.
All patients received aspirin (325 mg) daily for the entire
study period. Otherwise routine medical treatment of the
patients was not altered. Concomitant medications for the
treatment of dyslipidemia, diabetes (oral and insulin) had
to be documented as drug classes (yes/no), but no specific
medication was recorded.
Investigations
The baseline investigations included chest x-ray, electro-
cardiogram, bone density scan, urinalysis, stool for occult
blood, complete blood count, electrolytes (including
serum potassium, blood urea nitrogen [BUN] and cre-
atinine), liver function tests, prothrombin time (PT),
aPTT, lipid profile, lipoprotein, lipase, alpha-lipoprotein A
and B, and several other investigational measurements re-
lating to thrombosis. Patients were seen by the study coor-
dinators at 2 weeks, 4–6 weeks, 3 months, and 6 months
after the angioplasty.
Statistics and procedures
A total of 170 patients had to be enrolled to meet the
study aims as outlined previously [9]. Statistical evaluation
included paired, two sided t-test for each of the treatment
groups to compare baseline and follow-up values. The po-
tassium plasma levels were measured by routine repetitive
medical laboratory analyses using automated analyser
systems.
Results
The study was terminated before the target goal of 170
patients was completed. The reason for the termination
was declining enrollment for simple balloon angioplasty
in the face of the introduction of coronary atherectomy
and stents. Therefore a total of 118 patients with 158
lesions treated with angioplasty were enrolled. For 117
patients data on serum potassium throughout months 0
to 6 were available and 102 patients completed the study
and had a follow-up quantitative coronary angiography.
Seven patients withdrew and refused to continue. Three
patients were withdrawn by their physicians because of
new medical conditions which developed. Two patients
were discontinued because of hematuria. Four patients
were lost to follow-up.
Patients had a mean age of 59 years, 84.6% were male
and the majority (n = 103) of caucasian origin. Patients
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gender and race (Table 1). The distribution of vessels
treated during angioplasty showed that the left anterior
descending coronary artery (LAD) was more frequently
treated in the LMWH group.
Serum potassium values at baseline and for the follow-
up visits are shown in Figure 1. There was a statistically
significant increase in serum potassium at two weeks
after discharge compared to baseline (p < 0.001) in either
group which remained elevated throughout the three
months treatment phase (p < 0.05 vs. baseline). Differ-
ences between treatment groups were not statistically
significant (Table 2). Overall 12 out of 59 patients receiv-
ing certoparin (20.3%) and 11 out of 58 patients receiving
placebo (19.0%) experienced hyperkalemia based on
threshold of >5.0 mmol/l. After treatment discontinuation
at the three months visit serum potassium returned to
normal values (p = n.s. vs. baseline) in both groups.
Discussion
First case reports of patients with heparin induced hyper-
kalemia date back to 1980 where Phelps and colleagues
published the case of a 77 year old man with a creatinine
clearance of 23 to 27 ml/min who developed hyperkalemia
while receiving heparin for peripheral arterial insufficiency
[10]. Discontinuation of heparin led to resolution of
hyperkalemia as the plasma aldosterone concentrationTable 1 Baseline characteristics











Blood urea (mmol/l) Mean ± SD
Min
Max
Serum creatinine (mg/dl) Mean ± SD
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Max
eGFR (ml/min) Mean ± SD
Min
Maxmultiplied six-fold. Since then a total of 6 clinical stud-
ies [1,2,7,8,11,12] have been published on this issue (as
to a PubMed search dated September 2014 with the
keywords heparin & hyperkalemia and the restriction
“clinical trial”, the latest being the work of Torres et al.
in May 2010 reflecting the continued clinical implica-
tion of this rare but relevant complication [7].
Heparin-induced increases in serum potassium are
mediated by a reversible effect of heparin on aldosterone
leading to hypoaldosteronism [2,3]. It is effected by both
a reduction of the number and affinity of angiotensin II
receptors in the zona glomerulosa [4]. Prolonged heparin
application has been shown to result in a reduced width
of the adrenal zona glomerulosa, an effect that appears
to be more pronounced with UFH than LMWH [12,13].
Available studies on LMWH induced hyperkalemia have
usually compared incidence rates with those observed
with UFH [6,12,14] or were purely observational [7,15].
These studies suggested that hyperkalemia rates with
LMWH were as high [6] or even lower [12] than those
with UFH. No study has however reported rates for
LMWH as compared to placebo. Our own post-hoc ana-
lysis of a trial involving patients undergoing coronary
angioplasty revealed no significant differences between
the LMWH certoparin (at 8,000 I.U. aXa per day) and
placebo without any significant differences in serum po-
tassium and hyperkalemia over a three months period.Certoparin (n = 59) Placebo (n = 58)
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Certoparin 8,000 IU aXa
Figure 1 Serum potassium (mean ± standard deviation) with certoparin or placebo. Compared to baseline, there is a statistically significant
increase of serum potassium in the treatment period in either group. Legend: n.s., non significant; the statistical evaluation was performed using
paired, two sided t-test for each of the treatment groups to compare baseline and follow-up values.
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in hyperkalemia is potentially important in our analysis
because there was a UFH run-in period of 12–24 hours
after coronary angioplasty, after which patients were
randomized to receive certoparin or placebo. This run-
in period was, however, rather short compared to the
time course of hyperkalemia development in different
analyses [1], suggesting (but not excluding) no interfer-
ence of UFH with the later potassium values.
There was an increase of serum potassium within the
two weeks after hospital discharge however that might
have been precipitated by adjuvants present in the solu-
tion for injection or the prescription of drugs inducing
hyperkalemia in either group such as ACE inhibitors or
spironolactone or the discontinuation of diuretics. The
role of concomitant treatments is actually the result of a
previous report demonstrating that baseline potassium
and concomitant angiotensin converting enzyme (ACE)Table 2 Potassium values
Mean ± SD (mmol/l)
Certo Plac p-value**
Baseline 4.2 ± 0.4 4.2 ± 0.4 p = n.s.
Discharge 4.2 ± 0.4 4.2 ± 0.4 p = n.s.
2 weeks 4.5 ± 0.4 4.5 ± 0.4 p = n.s.
4-6 weeks 4.4 ± 0.4 4.4 ± 0.4 p = n.s.
3 months 4.4 ± 0.3 4.5 ± 0.3 p = n.s.
6 months 4.3 ± 0.3 4.3 ± 0.4 p = n.s.
Legend: *there were no patients with a serum potassium > 6.0 mmol/l; **the statisti
treatment groups to compare baseline and follow-up values.inhibitor use [7] predicted the development of hyperka-
lemia. We were not able to verify this since detailed data
on concomitant drug treatment (neither specific drugs
not doses) were not obtained.
Our results are in principal agreement with a prior
observational study by Abdel-Raheem who reported no
major increase in serum potassium with 2×40 mg enoxa-
parin per day [15]. It is in partial contrast, however, to a
warning in the summary of product characteristics (SPCs)
of enoxaparin and certoparin that potassium should be
monitored in patients with increased serum potassium
and those with a high risk. The SPC of tinzaparin even
tells that serum potassium has to be monitored in short
intervals.
The results are, of course, of particular relevance for
the population under investigation in the PARAT trial.
These were characterized by a referral for elective balloon
angioplasty. They had significant coronary artery disease> 5 to ≤5.5 mmol/l (%) > 5.5 mmol/l (%)*
Certo Plac Certo Plac
3.5 0 0 0
3.9 4 0 0
8.3 6 0 2
8.9 4.3 0 2.2
4.8 4.4 0 0
4.9 2.4 0 0
cal evaluation was performed using paired, two sided t-test for each of the
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concomitant conditions were hypertension (50.0%),
diabetes (13.6%), prior PTCA (20.3%) and prior CABG
(7.6%). In addition these patients frequently present
with risk factors for the development of hyperkalemia
such as impaired kidney function and often receive a
prescription of drugs increasing serum potassium levels in
its own (spironolactone and ACE inhibitors). Therefore
the population under investigation represent a high-risk
population for the development of hyperkalemia and
lesser rates can be expected for patients receiving LMWH
overall.
Limitations
There are a number of limitations for this analysis that
need consideration: 1) The sample size was rather small
with 107 being available for the potassium analyses in
both groups combined. At a rate of hyperkalemia of
20.3% for certoparin and 19.0% for placebo several thou-
sand patients would be necessary to determine a statisti-
cally significant difference. Even in this case the clinical
value of such a difference may be limited. 2) Concomitant
medication may interfere with the risk of hyperkalemia up
and beyond heparin or placebo. In the CRF only the
presence of drugs for the treatment of dyslipidemia and
diabetes (oral and insulin) were recorded, but no spe-
cific drugs nor those in particular with an interaction
potential on serum potassium.
Conclusions
We conclude that there is no incremental risk of hyper-
kalemia with certoparin up to 8,000 I.U. aXa per day
versus placebo in patients with coronary artery disease.
However the increase in serum potassium values after
hospital discharge in either group call for clinical sur-
veillance and the consideration of further risk factors
predisposing to hyperkalemia such as renal impairment,
diabetes mellitus and concomitant pharmacotherapy such
as ACE inhibitors and aldosterone antagonists.
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